证券之星消息，截至2025年12月8日收盘，五洲医疗(301234)报收于39.76元，上涨2.47%，换手率 2.66%，成交量1.81万手，成交额7189.95万元。 12月8日的资金流向数据方面，主力资金净流入329.85万元，占总成交额4.59%，游资资金净流入514.0 万元，占总成交额7.15%，散户资金净流出843.85万元，占总成交额11.74%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-08 | 39.76 | 2.47% | 329.85万 | 4.59% | 514.00万 | 7.15% | -843.85万 | -11.74% | | 2025-12-05 | 38.80 | 5.15% | ● 111.15万 | 2.16% | 218.75万 | 4.26% | -329.91万 | -6.42% | | 2025-12-04 | | 36. ...

Core Viewpoint - Wuzhou Medical (301234) experienced a decline in stock price, closing at 39.3 yuan on November 18, 2025, with a drop of 2.19% and a trading volume of 9,135 hands, amounting to a total transaction value of 36.3 million yuan [1] Group 1: Stock Performance and Trading Data - On November 18, 2025, the net outflow of main funds was 626.71 thousand yuan, accounting for 17.26% of the total transaction value, while retail investors saw a net inflow of 405.29 thousand yuan, representing 11.16% of the total [1] - The stock's performance over the past five days shows a downward trend, with the highest closing price at 41.29 yuan on November 13, 2025, and a total net outflow of main funds on November 17 and 18 [2] Group 2: Financial Metrics and Industry Comparison - Wuzhou Medical's total market value is 2.672 billion yuan, significantly lower than the industry average of 11.405 billion yuan, ranking 112 out of 124 in the medical device industry [3] - The company's net profit for the first three quarters of 2025 was 18.51 million yuan, a decrease of 46.09% year-on-year, with a gross margin of 14.22%, which is substantially below the industry average of 51.22% [3] - The company's return on equity (ROE) stands at 2.43%, outperforming the industry average of 0.15%, indicating some efficiency in generating profits from equity [3]

Core Viewpoint - The stock of Wuzhou Medical (301234) has shown a decline in price and mixed capital flow, indicating potential challenges in market performance and investor sentiment [1][2]. Financial Performance - As of November 17, 2025, Wuzhou Medical's stock closed at 40.18 yuan, down 1.76% with a trading volume of 11,200 hands and a transaction amount of 44.91 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 128 million yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 7.99 million yuan, down 36.39% year-on-year [3]. - For the first three quarters of 2025, the company's main revenue was 345 million yuan, up 0.82% year-on-year, while the net profit decreased by 46.09% to 18.51 million yuan [3]. Capital Flow Analysis - On November 17, 2025, the net inflow of main funds was 695,700 yuan, accounting for 1.55% of the total transaction amount, while retail investors experienced a net outflow of 2.34 million yuan, representing 5.20% of the total [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant retail outflows on November 14 and 13, indicating a potential shift in investor confidence [2]. Industry Comparison - Wuzhou Medical's total market value is 2.732 billion yuan, significantly lower than the industry average of 11.459 billion yuan, ranking 111 out of 124 in the medical device sector [3]. - The company's net profit margin stands at 5.36%, below the industry average of 9.57%, and its gross margin is 14.22%, compared to the industry average of 51.22%, indicating operational challenges [3].

Core Viewpoint - The stock of Wuzhou Medical (301234) has shown a decline in price and mixed capital flow, indicating potential challenges in market sentiment and financial performance [1][2]. Financial Performance - As of November 7, 2025, Wuzhou Medical's stock closed at 39.94 yuan, down 1.19% with a trading volume of 8,708 hands and a transaction value of 34.96 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 128 million yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 7.99 million yuan, down 36.39% year-on-year [3]. - For the first three quarters of 2025, the company's main revenue was 345 million yuan, up 0.82% year-on-year, while the net profit decreased by 46.09% to 18.51 million yuan [3]. Capital Flow Analysis - On November 7, 2025, the net outflow of main funds was 2.61 million yuan, accounting for 7.47% of the total transaction value, while retail investors saw a net inflow of 2.69 million yuan, representing 7.68% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from main funds on November 6 and 7, indicating a bearish sentiment [2]. Industry Comparison - Wuzhou Medical's total market value is 2.716 billion yuan, significantly lower than the industry average of 11.464 billion yuan, ranking 111 out of 124 in the medical device industry [3]. - The company's net profit margin stands at 5.36%, below the industry average of 9.57%, and its gross margin is 14.22%, compared to the industry average of 51.22% [3].

Core Viewpoint - Wuzhou Medical (301234) experienced a stock price increase of 6.13% on October 13, 2025, closing at 46.22 yuan, with a trading volume of 32,400 hands and a total transaction amount of 147 million yuan [1] Group 1: Stock Performance and Trading Data - On October 13, 2025, the main funds had a net outflow of 20.95 million yuan, accounting for 14.25% of the total transaction amount, while retail investors had a net inflow of 17.15 million yuan, representing 11.67% of the total [1] - Over the past five days, the stock's closing prices and changes were as follows: - October 13: 46.22 yuan (+6.13%) - October 10: 43.55 yuan (-2.73%) - October 9: 44.77 yuan (+2.92%) - September 30: 43.50 yuan (+0.35%) - September 29: 43.35 yuan (+3.17%) [2] Group 2: Financing and Margin Trading - On October 13, 2025, the financing balance was 95.73 million yuan, with a net financing purchase of 5.77 million yuan [3] - The financing data for the past five days showed fluctuations in financing balance and net purchases, with the highest net purchase recorded on October 13 [3] Group 3: Company Financials and Industry Comparison - Wuzhou Medical reported a main revenue of 217 million yuan for the first half of 2025, a year-on-year increase of 2.26%, but a net profit of 10.52 million yuan, a decrease of 51.69% [5] - Key financial metrics for Wuzhou Medical compared to the medical device industry average include: - Total Market Value: 3.159 billion yuan vs. 11.912 billion yuan - Net Assets: 753 million yuan vs. 3.889 billion yuan - Net Profit: 10.5151 million yuan vs. 149 million yuan - PE Ratio: 150.19 vs. 66.32 - Gross Margin: 14.33% vs. 51.85% [5]

Core Viewpoint - The stock of Wuzhou Medical (301234) has shown a slight increase in price, with significant fluctuations in capital flow, indicating mixed investor sentiment and performance challenges in the medical device industry [1][2]. Financial Performance - As of October 9, 2025, Wuzhou Medical's stock closed at 44.77 yuan, up 2.92%, with a trading volume of 19,800 hands and a transaction amount of 87.88 million yuan [1]. - The company reported a main revenue of 217 million yuan for the first half of 2025, a year-on-year increase of 2.26%, but the net profit attributable to shareholders decreased by 51.69% to 10.52 million yuan [3]. - The second quarter of 2025 saw a decline in main revenue to 113 million yuan, down 7.58% year-on-year, and a net profit of 4.88 million yuan, down 58.93% year-on-year [3]. Capital Flow Analysis - On October 9, 2025, the net inflow of main funds was 2.32 million yuan, accounting for 2.64% of the total transaction amount, while retail investors experienced a net outflow of 11.87 million yuan, representing 13.51% of the total [1][2]. - Over the past five days, the capital flow has shown fluctuations, with notable net inflows from retail investors on some days, but overall, the sentiment appears cautious [2]. Industry Comparison - Wuzhou Medical's total market value is 3.044 billion yuan, significantly lower than the industry average of 12.177 billion yuan, ranking 104th out of 123 in the medical device sector [3]. - Key financial ratios indicate that Wuzhou Medical has a price-to-earnings ratio of 144.76, which is considerably higher than the industry average of 67.16, suggesting overvaluation concerns [3]. - The company's gross margin stands at 14.33%, well below the industry average of 51.85%, indicating potential operational inefficiencies [3].

Core Viewpoint - The stock of Wuzhou Medical (301234) has shown a slight increase, with a closing price of 40.52 yuan on August 18, 2025, reflecting a 0.47% rise, while the company faces challenges in profitability and market position within the medical device industry [1][3]. Financial Performance - Wuzhou Medical reported a main business revenue of 104 million yuan for Q1 2025, representing a year-on-year increase of 15.59% [3]. - The net profit attributable to shareholders was 5.63 million yuan, down 43.0% year-on-year, and the non-recurring net profit was 4.56 million yuan, down 44.82% year-on-year [3]. - The company's debt ratio stands at 10.75%, with investment income of 1.96 million yuan and financial expenses of -1.15 million yuan [3]. Market Position and Valuation - Wuzhou Medical's total market capitalization is 2.755 billion yuan, significantly lower than the industry average of 12.121 billion yuan, ranking 112 out of 123 in the medical device sector [3]. - The company has a price-to-earnings (P/E) ratio of 122.25, compared to the industry average of 78.11, indicating a higher valuation relative to earnings [3]. - The gross margin is 14.62%, substantially below the industry average of 51.35%, ranking 120 out of 123 [3]. Capital Flow Analysis - On August 18, 2025, the net outflow of main funds was 3.97 million yuan, accounting for 2.98% of the total transaction amount, while retail funds saw a net outflow of 1.42 million yuan, representing 1.07% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows from retail investors on certain days, indicating varying investor sentiment [2].